289 related articles for article (PubMed ID: 24334458)
41. Transforming growth factor-β 1 enhances the invasiveness of breast cancer cells by inducing a Smad2-dependent epithelial-to-mesenchymal transition.
Lv ZD; Kong B; Li JG; Qu HL; Wang XG; Cao WH; Liu XY; Wang Y; Yang ZC; Xu HM; Wang HB
Oncol Rep; 2013 Jan; 29(1):219-25. PubMed ID: 23129177
[TBL] [Abstract][Full Text] [Related]
42. Inhibiting YAP expression suppresses pancreatic cancer progression by disrupting tumor-stromal interactions.
Jiang Z; Zhou C; Cheng L; Yan B; Chen K; Chen X; Zong L; Lei J; Duan W; Xu Q; Li X; Wang Z; Ma Q; Ma J
J Exp Clin Cancer Res; 2018 Mar; 37(1):69. PubMed ID: 29587800
[TBL] [Abstract][Full Text] [Related]
43. Negative control of TRAIL-R1 signaling by transforming growth factor β1 in pancreatic tumor cells involves Smad-dependent down regulation of TRAIL-R1.
Radke DI; Ungefroren H; Helm O; Voigt S; Alp G; Braun H; Hübner S; Dilchert J; Sebens S; Adam D; Kalthoff H; Trauzold A
Cell Signal; 2016 Nov; 28(11):1652-62. PubMed ID: 27492861
[TBL] [Abstract][Full Text] [Related]
44. Nox4-derived ROS signaling contributes to TGF-β-induced epithelial-mesenchymal transition in pancreatic cancer cells.
Hiraga R; Kato M; Miyagawa S; Kamata T
Anticancer Res; 2013 Oct; 33(10):4431-8. PubMed ID: 24123012
[TBL] [Abstract][Full Text] [Related]
45. Biomarkers of TGF-β signaling pathway and prognosis of pancreatic cancer.
Javle M; Li Y; Tan D; Dong X; Chang P; Kar S; Li D
PLoS One; 2014; 9(1):e85942. PubMed ID: 24465802
[TBL] [Abstract][Full Text] [Related]
46. Role of BCL9L in transforming growth factor-β (TGF-β)-induced epithelial-to-mesenchymal-transition (EMT) and metastasis of pancreatic cancer.
Sannino G; Armbruster N; Bodenhöfer M; Haerle U; Behrens D; Buchholz M; Rothbauer U; Sipos B; Schmees C
Oncotarget; 2016 Nov; 7(45):73725-73738. PubMed ID: 27713160
[TBL] [Abstract][Full Text] [Related]
47. WNT/β-catenin signal inhibitor IC-2-derived small-molecule compounds suppress TGF-β1-induced fibrogenic response of renal epithelial cells by inhibiting SMAD2/3 signalling.
Hoi S; Tsuchiya H; Itaba N; Suzuki K; Oka H; Morimoto M; Takata T; Isomoto H; Shiota G
Clin Exp Pharmacol Physiol; 2020 Jun; 47(6):940-946. PubMed ID: 32012313
[TBL] [Abstract][Full Text] [Related]
48. Vasohibin-2 is required for epithelial-mesenchymal transition of ovarian cancer cells by modulating transforming growth factor-β signaling.
Norita R; Suzuki Y; Furutani Y; Takahashi K; Yoshimatsu Y; Podyma-Inoue KA; Watabe T; Sato Y
Cancer Sci; 2017 Mar; 108(3):419-426. PubMed ID: 28064471
[TBL] [Abstract][Full Text] [Related]
49. SMAD2/3 mediate oncogenic effects of TGF-β in the absence of SMAD4.
Bertrand-Chapel A; Caligaris C; Fenouil T; Savary C; Aires S; Martel S; Huchedé P; Chassot C; Chauvet V; Cardot-Ruffino V; Morel AP; Subtil F; Mohkam K; Mabrut JY; Tonon L; Viari A; Cassier P; Hervieu V; Castets M; Mauviel A; Sentis S; Bartholin L
Commun Biol; 2022 Oct; 5(1):1068. PubMed ID: 36207615
[TBL] [Abstract][Full Text] [Related]
50. miR-367 promotes epithelial-to-mesenchymal transition and invasion of pancreatic ductal adenocarcinoma cells by targeting the Smad7-TGF-β signalling pathway.
Zhu Z; Xu Y; Zhao J; Liu Q; Feng W; Fan J; Wang P
Br J Cancer; 2015 Apr; 112(8):1367-75. PubMed ID: 25867271
[TBL] [Abstract][Full Text] [Related]
51. SMAD4 endows TGF-β1-induced highly invasive tumor cells with ferroptosis vulnerability in pancreatic cancer.
Chen HD; Ye Z; Hu HF; Fan GX; Hu YH; Li Z; Li BR; Ji SR; Zhou CJ; Xu XW; Yu XJ; Qin Y
Acta Pharmacol Sin; 2024 Apr; 45(4):844-856. PubMed ID: 38057506
[TBL] [Abstract][Full Text] [Related]
52. Autophagy links β-catenin and Smad signaling to promote epithelial-mesenchymal transition via upregulation of integrin linked kinase.
Pang M; Wang H; Rao P; Zhao Y; Xie J; Cao Q; Wang Y; Wang YM; Lee VW; Alexander SI; Harris DC; Zheng G
Int J Biochem Cell Biol; 2016 Jul; 76():123-34. PubMed ID: 27177845
[TBL] [Abstract][Full Text] [Related]
53. Antitumor activity of TGF-beta inhibitor is dependent on the microenvironment.
Medicherla S; Li L; Ma JY; Kapoun AM; Gaspar NJ; Liu YW; Mangadu R; O'Young G; Protter AA; Schreiner GF; Wong DH; Higgins LS
Anticancer Res; 2007; 27(6B):4149-57. PubMed ID: 18229422
[TBL] [Abstract][Full Text] [Related]
54. Up-regulation of L1CAM in pancreatic duct cells is transforming growth factor beta1- and slug-dependent: role in malignant transformation of pancreatic cancer.
Geismann C; Morscheck M; Koch D; Bergmann F; Ungefroren H; Arlt A; Tsao MS; Bachem MG; Altevogt P; Sipos B; Fölsch UR; Schäfer H; Müerköster SS
Cancer Res; 2009 May; 69(10):4517-26. PubMed ID: 19435915
[TBL] [Abstract][Full Text] [Related]
55. Lunatic Fringe is a potent tumor suppressor in Kras-initiated pancreatic cancer.
Zhang S; Chung WC; Xu K
Oncogene; 2016 May; 35(19):2485-95. PubMed ID: 26279302
[TBL] [Abstract][Full Text] [Related]
56. TGF-β signaling promotes tube-structure-forming growth in pancreatic duct adenocarcinoma.
Yamaguchi T; Ikehara S; Akimoto Y; Nakanishi H; Kume M; Yamamoto K; Ohara O; Ikehara Y
Sci Rep; 2019 Aug; 9(1):11247. PubMed ID: 31375695
[TBL] [Abstract][Full Text] [Related]
57. CK2 inhibitor CX-4945 blocks TGF-β1-induced epithelial-to-mesenchymal transition in A549 human lung adenocarcinoma cells.
Kim J; Hwan Kim S
PLoS One; 2013; 8(9):e74342. PubMed ID: 24023938
[TBL] [Abstract][Full Text] [Related]
58. Negative regulation of TGF-β1-induced MKK6-p38 and MEK-ERK signalling and epithelial-mesenchymal transition by Rac1b.
Witte D; Otterbein H; Förster M; Giehl K; Zeiser R; Lehnert H; Ungefroren H
Sci Rep; 2017 Dec; 7(1):17313. PubMed ID: 29229918
[TBL] [Abstract][Full Text] [Related]
59. MiR-361-3p regulates ERK1/2-induced EMT via DUSP2 mRNA degradation in pancreatic ductal adenocarcinoma.
Hu J; Li L; Chen H; Zhang G; Liu H; Kong R; Chen H; Wang Y; Li Y; Tian F; Lv X; Li G; Sun B
Cell Death Dis; 2018 Jul; 9(8):807. PubMed ID: 30042387
[TBL] [Abstract][Full Text] [Related]
60. Embigin is overexpressed in pancreatic ductal adenocarcinoma and regulates cell motility through epithelial to mesenchymal transition via the TGF-β pathway.
Jung DE; Kim JM; Kim C; Song SY
Mol Carcinog; 2016 May; 55(5):633-45. PubMed ID: 25773908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
